Reversing the PAI-1-induced fibrotic immune exclusion of solid tumor by multivalent CXCR4 antagonistic nano-permeator
Open Access
- 21 December 2022
- journal article
- research article
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 13 (7) , 3106-3120
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progressionNature Medicine, 2016
- Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironmentInternational Immunology, 2016
- The future of immune checkpoint therapyScience, 2015
- Development of Functional Poly(amido amine) CXCR4 Antagonists with the Ability to Mobilize Leukocytes and Deliver Nucleic AcidsAdvanced Healthcare Materials, 2014
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 2014
- Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid TumorsClinical Cancer Research, 2014
- Antifibrotic effects of CXCR4 antagonist in bleomycin-induced pulmonary fibrosis in miceThe Journal of Medical Investigation, 2013
- Identification of Anti-Malarial Compounds as Novel Antagonists to Chemokine Receptor CXCR4 in Pancreatic Cancer CellsPLOS ONE, 2012
- The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisitedNature Reviews Cancer, 2003
- Bleomycin-induced pulmonary fibrosis in fibrinogen-null miceJournal of Clinical Investigation, 2000